First, the plastic is broken down into small components using chemicals. These components are then used as nutrients for genetically modified bacteria, according to Forskning.no.
The bacteria are programmed to perform a new function: converting plastic into the compound levodopa.
Levodopa is used in the treatment of Parkinson’s disease. According to a study published in Nature Sustainability, the method demonstrates how waste can be given new value.
Limited impact
Although the idea is novel, its overall impact is limited. Far more plastic is produced globally than can be used for medicine production.
According to the United Nations, approximately 400 million tons of plastic are produced each year. At the same time, the demand for Parkinson’s medication is much lower.
A researcher from NTNU therefore assesses that the method does not solve the problem of plastic pollution. Moreover, there is currently no shortage of this type of medication.
Research rather than a solution
The method is primarily a research project. It demonstrates how scientists can alter the functions of bacteria.
The same research group has previously used similar methods to produce other substances, such as flavorings and painkillers.
There are also challenges related to safety and approval. New production methods in the pharmaceutical industry require extensive testing and regulation.
This is not a new way of producing medicine, but rather a demonstration of what biotechnology can be used for.
Sources: Forskning.no, Nature Sustainability, and the United Nations.




























